Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Asset Growth Recovery in ProgressRecovering
Percentile Rank63
5Y CAGR-23.2%
Studio
Year-over-Year Change

Year-over-year total asset growth rate

5Y CAGR
-23.2%/yr
Long-term compound
Percentile
P63
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202546.17%
202419.82%
2023226.38%
2022-26.50%
202124.75%
2020172.82%
2019332.16%
2018-24.63%
20170.00%